JCOVDEN

This brand name is authorized in Estonia, France, Japan, Netherlands, Poland, South Africa, Spain, Tunisia.

Active ingredients

The drug JCOVDEN contains one active pharmaceutical ingredient (API):

1	COVID-19 Vaccine Janssen UNII B6L4N5Z4GH - SARS-COV-2
	SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is a monovalent vaccine composed of a recombinant, replicationincompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 full-length spike (S) glycoprotein in a stabilised conformation. Following administration, the S glycoprotein of SARSCoV-2 is transiently expressed, stimulating both neutralising and other functional S-specific antibodies, as well as cellular immune responses directed against the S antigen, which may contribute to protection against COVID-19.
	Read more about SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S)

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JCOVDEN Suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BN02		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1842319, 1845558
ES	Centro de información online de medicamentos de la AEMPS	1201525001
FR	Base de données publique des médicaments	64798803
JP	医薬品医療機器総合機構	631341HA1023
PL	Rejestru Produktów Leczniczych	100449317
TN	Direction de la Pharmacie et du Médicament	1527305EP
ZA	Health Products Regulatory Authority	55/30.5/0849